scholarly journals Memory Awareness Influences Everyday Decision Making Capacity about Medication Management in Alzheimer's Disease

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Stephanie Cosentino ◽  
Janet Metcalfe ◽  
Mark S. Cary ◽  
Jessica De Leon ◽  
Jason Karlawish
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Decision Making ◽  
Informed Consent ◽  
Medication Management ◽  
Memory Loss ◽  
Decision Making Capacity ◽  
Memory Awareness ◽  
Early Alzheimer’S Disease

Memory awareness in early Alzheimer’s disease (AD) influences capacity to provide informed consent for a memory treatment. This study investigated the extent to which aspects of memory awareness influence everyday decision-making capacity about medication management in AD. 42 participants with mild AD and 50 healthy elders underwent clinical ratings of memory awareness, metamemory testing, and an interview of everyday decision-making capacity regarding medication management. 45% of AD subjects were classified as aware (AAD) and 55% as unaware (UAD) based on clinical ratings and supported by metamemory testing (P=.015). Capacity was impaired in each of the AD groups as compared to the healthy eldersF(2, 67)=17.63, UAD,P<.01; AAD,P=.01). Within the AD group, capacity correlated selectively with awareness as measured with clinical ratings (r=−.41,P=.007) but not objective metamemory testing (r=−.10,P=.60). Appreciation scores were lower in UAD as compared with AADF(1, 35)=8.36,P=.007. Unawareness of memory loss should heighten clinicians’ concern about everyday decision-making capacity in AD.

scholarly journals P4-449: Memory awareness influences everyday decision making capacity in Alzheimer's disease

2011 ◽  
Vol 7 ◽  
pp. e68-e68
Author(s):  
Stephanie Cosentino ◽  
Janet Metcalfe ◽  
Mark Cary ◽  
Jason Karlawish
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Decision Making ◽  
Decision Making Capacity ◽  
Memory Awareness

P1-402: Memory awareness influences everyday decision making capacity in Alzheimer's disease

2011 ◽  
Vol 7 ◽  
pp. S241-S241 ◽  
Author(s):  
Stephanie Cosentino ◽  
Janet Metcalfe ◽  
Mark Cary ◽  
Jason Karlawish
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Decision Making ◽  
Decision Making Capacity ◽  
Memory Awareness

scholarly journals Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation

2020 ◽  
Vol 21 (5) ◽  
pp. 1746 ◽  
Author(s):  
Ana I. Duarte ◽  
Emanuel Candeias ◽  
Inês N. Alves ◽  
Débora Mena ◽  
Daniela F. Silva ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Nitrosative Stress ◽  
Senile Plaques ◽  
Memory Loss ◽  
Mature Female ◽  
Cognitive Changes ◽  
Female Mice ◽  
Early Alzheimer’S Disease

Alzheimer’s disease (AD) is the most common form of dementia worldwide, being characterized by the deposition of senile plaques, neurofibrillary tangles (enriched in the amyloid beta (Aβ) peptide and hyperphosphorylated tau (p-tau), respectively) and memory loss. Aging, type 2 diabetes (T2D) and female sex (especially after menopause) are risk factors for AD, but their crosslinking mechanisms remain unclear. Most clinical trials targeting AD neuropathology failed and it remains incurable. However, evidence suggests that effective anti-T2D drugs, such as the GLP-1 mimetic and neuroprotector liraglutide, can be also efficient against AD. Thus, we aimed to study the benefits of a peripheral liraglutide treatment in AD female mice. We used blood and brain cortical lysates from 10-month-old 3xTg-AD female mice, treated for 28 days with liraglutide (0.2 mg/kg, once/day) to evaluate parameters affected in AD (e.g., Aβ and p-tau, motor and cognitive function, glucose metabolism, inflammation and oxidative/nitrosative stress). Despite the limited signs of cognitive changes in mature female mice, liraglutide only reduced their cortical Aβ1–42 levels. Liraglutide partially attenuated brain estradiol and GLP-1 and activated PKA levels, oxidative/nitrosative stress and inflammation in these AD female mice. Our results support the earlier use of liraglutide as a potential preventive/therapeutic agent against the accumulation of the first neuropathological features of AD in females.

scholarly journals Thalamic pathology and memory loss in early Alzheimer’s disease: moving the focus from the medial temporal lobe to Papez circuit

Brain ◽  
2016 ◽  
Vol 139 (7) ◽  
pp. 1877-1890 ◽  
Author(s):  
John P. Aggleton ◽  
Agathe Pralus ◽  
Andrew J. D. Nelson ◽  
Michael Hornberger
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Temporal Lobe ◽  
Medial Temporal Lobe ◽  
Memory Loss ◽  
Papez Circuit ◽  
Early Alzheimer’S Disease

Do adapted vignettes improve medical decision-making capacity for individuals with Alzheimer's disease?

2017 ◽  
Vol 58 (6) ◽  
pp. 497-503 ◽  
Author(s):  
Liv Thalén ◽  
Katarina Heimann Mühlenbock ◽  
Ove Almkvist ◽  
Maria Eriksdotter ◽  
Erik Sundström ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Decision Making ◽  
Medical Decision Making ◽  
Medical Decision ◽  
Decision Making Capacity

Decisions and attitudes regarding participation and proxy in clinical trials among patients with impaired cognitive function

Dementia ◽  
2017 ◽  
Vol 18 (6) ◽  
pp. 2049-2061
Author(s):  
S Stormoen ◽  
IM Tallberg ◽  
O Almkvist ◽  
M Eriksdotter ◽  
E Sundström
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Decision Making ◽  
Clinical Trials ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
High Risk ◽  
Medical Decision Making ◽  
Medical Decision ◽  
Decision Making Capacity

Background Medical decision-making capacity is impaired in Alzheimer’s disease and mild cognitive impairment. Medical decision-making capacity depends on many different cognitive functions and varies due to situation and cognitive, social, and emotional status of the patient. Our aim was to analyze dementia patients’ capacity to estimate risks and benefits in different clinical trials and determine how cognitive decline affects their attitude toward possible participation and proxy consent. Methods Groups: Alzheimer’s disease (n = 20), mild cognitive impairment (n = 21) and healthy controls (n = 33). Two hypothetical clinical trials, a standardized interview and three visual analogue scales were used to investigate decisions, estimations, reasoning, and attitudes. Results A general positive attitude toward participation in clinical trials was shown among all groups. Both patients and controls motivated possible participation as “own-benefit” in the low-risk trial and to “help-others” in the high-risk trial. Individuals who accepted to participate in the high-risk trial scored lower in medical decision-making capacity in comparison to participants who would not have participated (p < .01). Patients in the Alzheimer’s disease but not mild cognitive impairment and healthy control groups underestimated risks and overestimated benefits in the high-risk/low-benefit trial (p < .05). A family member was most frequently chosen as possible proxy (91%). Conclusions Medical decisions and research consent should be interpreted with caution in patients who are already in early stages of dementia, as the patients’ acceptance to participate in high-risk trials may be due an insufficient decisional capacity and risk analysis, accelerated by a general desire to make good to society. We emphasize the use of a standardized tool to evaluate medical decisional capacity in clinical research.

scholarly journals Clinical Considerations in Physician-Assisted Death for Probable Alzheimer’s Disease: Decision-Making Capacity, Anosognosia, and Suffering

2019 ◽  
Vol 9 (2) ◽  
pp. 217-226 ◽  
Author(s):  
Jaime D. Mondragón ◽  
Latife Salame ◽  
Arnoldo Kraus ◽  
Peter Paul De Deyn
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Decision Making ◽  
Subjective Cognitive Decline ◽  
Clinical Approach ◽  
Early Assessment ◽  
Assisted Death ◽  
Clinical Prognosis ◽  
Decision Making Capacity ◽  
Testamentary Capacity

Background: Requests for physician-assisted death (PAD) in patients with cognitive impairment are complex and require careful consideration. Of particular difficulty is determination of whether the request is voluntary and well considered. Results: Euthanasia and physician-assisted suicide (PAS) are both legal in The Netherlands, Luxemburg, Colombia, and Canada. Euthanasia is legal in Belgium, while PAS is legal in Switzerland and Oregon, Washington, Montana, Vermont, and California (USA). Upon a PAD request, evaluation of the capacity to consent medical treatment is relevant for the decision-making process, while evaluation of testamentary capacity is appropriate before an advance euthanasia directive is written. Anosognosia assessment throughout the Alzheimer’s disease continuum provides essential and relevant information regarding the voluntary and well-considered nature of the PAD request; meanwhile, early assessment of hypernosognosia or subjective cognitive decline assists in formulation of a clinical prognosis. Furthermore, the assessment of physical and psychological suffering should incorporate verbal and nonverbal cues as well as consideration of the psychosocial factors that might affect due care criteria. Conclusion: The clinical approach to a PAD request should consider the legal framework and the decision-making capacity, assess memory deficit awareness and the perception of suffering, and evaluate mental competency when considered pertinent.

Sign in / Sign up

Export Citation Format

Share Document